AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Optimal Time for Reperfusion in Acute Pulmonary Embolism

Recruitingn/aAges 18 Years - anyAllAzienda ULSS 8 Berica
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Pulmonary embolism (PE) is the third leading cause of cardiovascular mortality worldwide. Current guidelines recommend early reperfusion for high-risk and intermediate-high-risk PE, yet systemic thrombolysis and percutaneous therapies are frequently underutilized, and no specific timing for reperfusion is defined, unlike in acute myocardial infarction or ischemic stroke. As most PE-related in-hospital deaths occur within the first hours and thrombus composition changes over time, defining an optimal reperfusion time window may improve survival and prevent hemodynamic deterioration. We therefore propose a national, multicenter, prospective observational study to evaluate the prognostic impact of reperfusion timing, using systemic thrombolysis or catheter-directed therapies, on in-hospital mortality and haemorrhagic or cardiovascular complications.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Age โ‰ฅ 18 years * Patients with a diagnosis of intermediate-high or high pulmonary embolism confirmed by computed tomography pulmonary angiography (CTPA), pulmonary angiography, or echocardiography (evidence of a floating thrombus in the right atrium or right ventricle, or proximal visualization of thrombus in the pulmonary artery). * Classified as high-risk or intermediate-high-risk according to the 2019 European Society of Cardiology guidelines. * Provision of informed consent for the processing of personal data. Exclusion Criteria: * Age \< 18 years * Patients in whom a diagnosis of acute high-risk or intermediate-high-risk pulmonary embolism has been excluded. * Inability to provide informed consent.
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

7 sites
UO Unitร  di Cure Intensive Cardiologiche e Cardiologia 1, Ospedale Niguarda, Milano
Milan, Italy
UOC di Cardiologia, Ospedali Riuniti Padova Sud, Monselice, Italia
Monselice, Italy
IRCCS Policlinico San Matteo
Pavia, Italy
UO di Sezione di Medicina Interna e Cardiovascolare, Ospedale Santa Maria della Misericordia, Perugia, Italia
Perugia, Italy
UO di Cardiologia 1, Azienda Ospedaliero Universitaria Pisana, Pisa, Italia
Pisa, Italy
UO di Cardiologia, Azienda Ospedaliera Ordine Mauriziano di Torino
Torino, Italy
UOC di Cardiologia, Ospedali dell'Ovest Vicentino, Arzignano, IItalia
Arzignano, Italy
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy